吡柔比星和环磷酰胺联合多西他赛对乳腺癌的临床疗效观察

Clinical Efficacy of Pirarubicin and Cyclophosphamide Combined with Docetaxel for Breast Cancer

目的探讨吡柔比星和环磷酰胺联合多西他赛对进展期乳腺癌的临床疗效。方法Ⅱ~Ⅲ期择期手术乳腺癌患者116例,随机分为两组,每组58例。TAC组采用吡柔比星和环磷酰胺联合多西他赛治疗方案,CAF组采用吡柔比星和环磷酰胺联合氟尿嘧啶治疗方案,对比分析两组患者的临床疗效和不良反应。结果化疗结束后,与CAF组相比,TAC组患者的KPS得分、病理完全缓解率和总有效率有统计学意义(P<0.05)。TAC组和CAF组的腋窝淋巴结转阴率分别为35.6%和22.7%,差异有统计学意义(P<0.05)。不良反应中,两组白细胞减少率、粒细胞减少率、脱发发生率比较,差异均有统计学意义(P<0.05);而血小板减少率、恶心呕吐发生率、心脏毒性发生率比较,差异均无统计学意义(P>0.05)。结论 TAC方案可作为乳腺癌手术患者的新辅助化疗方案,疗效较好。

Objective To investigate the clinical efficacy of pirarubicin and cyclophosphamide combined with docetaxel for advanced breast cancer.Methods 116 patients with Ⅱ ~ Ⅲ stage breast cancer were randomly divided into 2 groups with 58 cases in each.TAC group was treated with pirarubicin and cyclophosphamide combined with docetaxel treatment,CAF group were treated with pirarubicin and cyclophosphamide combined with fluorouracil treatment,the clinical efficacy and adverse reactions of both groups were compared.Results After chemotherapy,there had statistically significant difference in KPS score,pathological complete remission rate and total efficiency between the 2 groups(P < 0.05).Axillary lymph node negative rates in TAC group and CAF group were 35.6% and 22.7%,the difference was statistically significant(P < 0.05).Adverse reactions of the 2groups,the white blood cell reduction rate,neutropenia,alopecia incidence rate had statistically significant difference(P < 0.05);and the platelet reduction rate,the incidence of nausea and vomiting,the occurrence of cardiac toxicity had no statistically significant difference(P > 0.05).Conclusion TAC regimen as neoadjuvant chemotherapy for breast cancer operation is effective.